Related references
Note: Only part of the references are listed.In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides
Amber L. Southwell et al.
MOLECULAR THERAPY (2014)
Quantification Assays for Total and Polyglutamine-Expanded Huntingtin Proteins
Douglas Macdonald et al.
PLOS ONE (2014)
A fully humanized transgenic mouse model of Huntington disease
Amber L. Southwell et al.
HUMAN MOLECULAR GENETICS (2013)
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Holly B. Kordasiewicz et al.
NEURON (2012)
IP-FCM Measures Physiologic Protein-Protein Interactions Modulated by Signal Transduction and Small-Molecule Drug Inhibition
Stephen E. P. Smith et al.
PLOS ONE (2012)
Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene/Allele-Specific Silencing of Mutant Huntingtin
Jeffrey B. Carroll et al.
MOLECULAR THERAPY (2011)
Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington's disease
Andreas Weiss et al.
ANALYTICAL BIOCHEMISTRY (2009)
Sustained Effects of Nonallele-Specific Huntingtin Silencing
Valerie Drouet et al.
ANNALS OF NEUROLOGY (2009)
Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells
Tamara Ratovitski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease
Rona K. Graham et al.
JOURNAL OF NEUROSCIENCE (2009)
Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice
Michelle Gray et al.
JOURNAL OF NEUROSCIENCE (2008)
AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease
Nicholas R. Franich et al.
MOLECULAR THERAPY (2008)
R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice
Anton Reiner et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2007)
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits
M. DiFiglia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse
Y Machida et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA
YL Wang et al.
NEUROSCIENCE RESEARCH (2005)
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice
E Rodriguez-Lebron et al.
MOLECULAR THERAPY (2005)
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model
SQ Harper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
EJ Slow et al.
HUMAN MOLECULAR GENETICS (2003)
New anti-huntingtin monoclonal antibodies: Implications for huntingtin conformation and its binding proteins
J Ko et al.
BRAIN RESEARCH BULLETIN (2001)
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
A Yamamoto et al.
CELL (2000)
Share Paper
